Martin Lund Kårhus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin Lund Kårhus has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Ellegaard
Center for Clinical Metabolic Research, Copenhagen University Hospital – Herlev and Gentofte, Hellerup, Denmark
10 shared publications - Filip Krag Knop
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
10 shared publications - Line Lund Kårhus
Center for Clinical Research and Prevention, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Frederiksberg, Denmark
7 shared publications - Matilde Winther-Jensen
Center for Clinical Research and Prevention, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Frederiksberg, Denmark
6 shared publications - Asger Lund
Centre for Clinical Metabolic Research, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
1 shared publication - David Peick Sonne
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 28 April 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (9) , 13927-13933
Cholecystectomy and the subsequent risk of bile acid diarrhea: a retrospective nationwide cohort study
Background: Cholecystectomy is one of the most commonly performed surgical procedures worldwide, with a global prevalence of about 5%. A common side effect after cholecystectomy is post-cholecystectomy diarrhea, which can lead to bile acid diarrhea (BAD). BAD is a socially debilitating disease characterized by diarrhea, fecal urgency, and fecal incontinence. BAD is caused by excessive amounts of bile acids in the colon and is estimated to affect an estimated 1–2% of the population. Knowledge on the incidence of post-cholecystectomy BAD is lacking, and this nationwide cohort study investigated the incidence of BAD in individuals with and without a history of cholecystectomy. Materials and Methods: By using nationwide Danish health registries, individuals who had undergone a cholecystectomy were identified ( n = 148 834) and matched 1:10 to a reference population of age- and sex-matched individuals without cholecystectomy ( n = 1 487 914). BAD was defined as referral for a 75 selenium-homotaurocholic acid (SeHCAT) test followed by redemption of a bile acid sequestrant prescription within 365 days, or registration of a BAD diagnosis code. Results: A higher proportion of individuals with cholecystectomy were diagnosed with BAD compared to their matched controls (0.7% vs. 0.1%). Individuals who had undergone cholecystectomy had a higher cause-specific hazard of BAD (hazard ratio: 6.53, 95% confidence interval: 6.07–7.02) compared with matches. Conclusion: In this nationwide cohort study, individuals undergoing cholecystectomy had a seven-fold increased risk of developing BAD compared with an age- and sex-matched reference population, highlighting the importance of considering BAD as a potential comorbidity in individuals undergoing cholecystectomy.
- 28 April 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (9) , 13927-13933
Open AccessCholecystectomy and the subsequent risk of bile acid diarrhea: a retrospective nationwide cohort study
Background: Cholecystectomy is one of the most commonly performed surgical procedures worldwide, with a global prevalence of about 5%. A common side effect after cholecystectomy is post-cholecystectomy diarrhea, which can lead to bile acid diarrhea (BAD). BAD is a socially debilitating disease characterized by diarrhea, fecal urgency, and fecal incontinence. BAD is caused by excessive amounts of bile acids in the colon and is estimated to affect an estimated 1–2% of the population. Knowledge on the incidence of post-cholecystectomy BAD is lacking, and this nationwide cohort study investigated the incidence of BAD in individuals with and without a history of cholecystectomy. Materials and Methods: By using nationwide Danish health registries, individuals who had undergone a cholecystectomy were identified ( n = 148 834) and matched 1:10 to a reference population of age- and sex-matched individuals without cholecystectomy ( n = 1 487 914). BAD was defined as referral for a 75 selenium-homotaurocholic acid (SeHCAT) test followed by redemption of a bile acid sequestrant prescription within 365 days, or registration of a BAD diagnosis code. Results: A higher proportion of individuals with cholecystectomy were diagnosed with BAD compared to their matched controls (0.7% vs. 0.1%). Individuals who had undergone cholecystectomy had a higher cause-specific hazard of BAD (hazard ratio: 6.53, 95% confidence interval: 6.07–7.02) compared with matches. Conclusion: In this nationwide cohort study, individuals undergoing cholecystectomy had a seven-fold increased risk of developing BAD compared with an age- and sex-matched reference population, highlighting the importance of considering BAD as a potential comorbidity in individuals undergoing cholecystectomy.
- Open Access
- 23 May 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (7) , e00863
Bile Acid Diarrhea Is Associated With an Increased Risk of Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study
INTRODUCTION: Bile acid diarrhea (BAD) is a socially debilitating disease characterized by diarrhea, fecal urgency, and fecal incontinence. It is caused by excessive amounts of bile acids in the colon and is estimated to affect up to 1% of the population. Among other actions, bile acids regulate systemic glucose and lipid metabolism, and BAD has been associated with a dysmetabolic prediabetic-like state. Here, we investigate the association between BAD and type 2 diabetes (T2D) and cardiovascular disease (CVD), respectively. METHODS: By using nationwide Danish health registries, individuals with BAD were identified by referral to the diagnostic 75selenium-homotaurocholic acid test followed by redemption of a prescription of a bile acid sequestrant within 365 days or a BAD diagnosis code (n = 5,954). A reference population of age-matched and sex-matched individuals was included for comparison (n = 59,540). RESULTS: More individuals with BAD than controls developed T2D (8.8% vs 5.2%) and experienced CVD (22.7% vs 18.0%) after index date (i.e., BAD diagnosis or matching, respectively). Sensitivity analyses revealed earlier onset of T2D and CVD in the BAD population compared with matches but no difference between sexes. The cause-specific hazards for T2D and CVD were 1.79 and 1.34, respectively, in the BAD population compared with matches. All-cause mortality—but not CVD-related mortality—was increased among individuals with BAD compared with matches. DISCUSSION: BAD is associated with increased risk and earlier onset of T2D and CVD, respectively, as well as disturbed glucose and lipid metabolism, indicating BAD as a high-risk condition requiring intensified monitoring and relevant preventive interventions.
- 23 May 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (7) , e00863
Open AccessBile Acid Diarrhea Is Associated With an Increased Risk of Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study
INTRODUCTION: Bile acid diarrhea (BAD) is a socially debilitating disease characterized by diarrhea, fecal urgency, and fecal incontinence. It is caused by excessive amounts of bile acids in the colon and is estimated to affect up to 1% of the population. Among other actions, bile acids regulate systemic glucose and lipid metabolism, and BAD has been associated with a dysmetabolic prediabetic-like state. Here, we investigate the association between BAD and type 2 diabetes (T2D) and cardiovascular disease (CVD), respectively. METHODS: By using nationwide Danish health registries, individuals with BAD were identified by referral to the diagnostic 75selenium-homotaurocholic acid test followed by redemption of a prescription of a bile acid sequestrant within 365 days or a BAD diagnosis code (n = 5,954). A reference population of age-matched and sex-matched individuals was included for comparison (n = 59,540). RESULTS: More individuals with BAD than controls developed T2D (8.8% vs 5.2%) and experienced CVD (22.7% vs 18.0%) after index date (i.e., BAD diagnosis or matching, respectively). Sensitivity analyses revealed earlier onset of T2D and CVD in the BAD population compared with matches but no difference between sexes. The cause-specific hazards for T2D and CVD were 1.79 and 1.34, respectively, in the BAD population compared with matches. All-cause mortality—but not CVD-related mortality—was increased among individuals with BAD compared with matches. DISCUSSION: BAD is associated with increased risk and earlier onset of T2D and CVD, respectively, as well as disturbed glucose and lipid metabolism, indicating BAD as a high-risk condition requiring intensified monitoring and relevant preventive interventions.
- Open Access
- 14 January 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (3) , e00815
Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach
Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a 6-week randomized controlled trial, we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments in BAD management. Here, we review the literature on different GLP-1RAs in BAD treatment and outline their potential mode of actions, highlight knowledge gaps, and outline the need for further clinical evidence generation.
- 14 January 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (3) , e00815
Open AccessTreatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach
Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a 6-week randomized controlled trial, we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments in BAD management. Here, we review the literature on different GLP-1RAs in BAD treatment and outline their potential mode of actions, highlight knowledge gaps, and outline the need for further clinical evidence generation.
- Open Access
- 10 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1159-1160
Response to Borup et al
- 10 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1159-1160
Open AccessResponse to Borup et al
- Open Access
- 23 September 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (11) , e00772
Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea
INTRODUCTION: Both liraglutide and colesevelam improve bile acid diarrhea symptoms. Colesevelam binds excess amounts of diarrhea-causing bile acids in the colon, whereas the mode of action for liraglutide remains elusive. In this article, we examined the impact of colesevelam and liraglutide treatment on the concentrations of bile acids in serum and feces and the fecal microbiota composition to better understand the 2 drugs' modes of action. METHODS: Bile acid species were analyzed in serum and fecal samples from a randomized, double-blind, double-dummy trial at baseline and after 3 and 6 weeks of orally administered colesevelam (1,875 mg twice daily, n = 26) or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26) in patients with 75selenium-homotaurocholic acid test-verified, idiopathic, or postcholecystectomy bile acid diarrhea. Fecal microbiota composition was analyzed by 16S rRNA gene amplicon sequencing at the same time points. RESULTS: Colesevelam increased the fecal concentrations of all bile acid species, whereas it decreased serum concentrations of secondary bile acids. Liraglutide induced a small increase in serum unconjugated bile acid concentrations without affecting fecal bile acid concentrations. No changes in fecal microbiota composition were observed with either treatment. DISCUSSION: Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion, whereas liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.
- 23 September 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (11) , e00772
Open AccessLiraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea
INTRODUCTION: Both liraglutide and colesevelam improve bile acid diarrhea symptoms. Colesevelam binds excess amounts of diarrhea-causing bile acids in the colon, whereas the mode of action for liraglutide remains elusive. In this article, we examined the impact of colesevelam and liraglutide treatment on the concentrations of bile acids in serum and feces and the fecal microbiota composition to better understand the 2 drugs' modes of action. METHODS: Bile acid species were analyzed in serum and fecal samples from a randomized, double-blind, double-dummy trial at baseline and after 3 and 6 weeks of orally administered colesevelam (1,875 mg twice daily, n = 26) or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26) in patients with 75selenium-homotaurocholic acid test-verified, idiopathic, or postcholecystectomy bile acid diarrhea. Fecal microbiota composition was analyzed by 16S rRNA gene amplicon sequencing at the same time points. RESULTS: Colesevelam increased the fecal concentrations of all bile acid species, whereas it decreased serum concentrations of secondary bile acids. Liraglutide induced a small increase in serum unconjugated bile acid concentrations without affecting fecal bile acid concentrations. No changes in fecal microbiota composition were observed with either treatment. DISCUSSION: Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion, whereas liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.
- Open Access
- 24 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8047
Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544
We have with great interest read the recent review on the molecular mechanisms underlying bile acid diarrhea (BAD) by Yang et al
- 24 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8047
Open AccessComment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544
We have with great interest read the recent review on the molecular mechanisms underlying bile acid diarrhea (BAD) by Yang et al
- Open Access
- 8 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (10) , 2107-2113
Bile Acid Diarrhea Is Associated With an Increased Incidence of Gastrointestinal Cancers
INTRODUCTION: Bile acid diarrhea (BAD) is an underrecognized and socially debilitating disease caused by high concentrations of bile acids in the colon. Bile acids directly and indirectly promote carcinogenesis. In this article, we investigated whether individuals with BAD have an increased risk of gastrointestinal (GI) cancers. METHODS: By using the Danish health registries, adult individuals with BAD were identified by International Classification of Diseases 10th revision code K90.8 or referral to the diagnostic ⁷⁵selenium-homotaurocholic acid test followed by prescription of a bile acid sequestrant within 365 days (n = 5,245). Age- and sex-matched individuals without BAD were included for comparison (n = 52,450). We analyzed the cumulative incidence of GI cancers after BAD diagnosis and the odds ratios (ORs) of GI cancer 8 and 15 years before BAD diagnosis/matching. RESULTS: Cumulative incidence of GI cancer 6 years after BAD diagnosis/matching was 1.6% in the BAD group and 1.1% in controls (P = 0.01). The ORs of total GI cancer 8 and 15 years before BAD diagnosis were 6.16 (5.08–7.48) and 5.19 (4.28–6.29), respectively. Furthermore, 47 individuals with BAD (0.9%) and 250 (0.5%) controls died of GI cancer. DISCUSSION: This nationwide cohort study indicates an association between BAD and GI cancers. We found both a higher incidence of GI cancer after BAD diagnosis compared with controls and increased OR of GI cancer before BAD diagnosis. Bearing in mind the underdiagnosis of BAD, the delay of BAD diagnosis, and the carcinogenic effect of bile acids, these findings warrant further investigations of the risk of GI cancer in individuals with BAD.
- 8 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (10) , 2107-2113
Open AccessBile Acid Diarrhea Is Associated With an Increased Incidence of Gastrointestinal Cancers
INTRODUCTION: Bile acid diarrhea (BAD) is an underrecognized and socially debilitating disease caused by high concentrations of bile acids in the colon. Bile acids directly and indirectly promote carcinogenesis. In this article, we investigated whether individuals with BAD have an increased risk of gastrointestinal (GI) cancers. METHODS: By using the Danish health registries, adult individuals with BAD were identified by International Classification of Diseases 10th revision code K90.8 or referral to the diagnostic ⁷⁵selenium-homotaurocholic acid test followed by prescription of a bile acid sequestrant within 365 days (n = 5,245). Age- and sex-matched individuals without BAD were included for comparison (n = 52,450). We analyzed the cumulative incidence of GI cancers after BAD diagnosis and the odds ratios (ORs) of GI cancer 8 and 15 years before BAD diagnosis/matching. RESULTS: Cumulative incidence of GI cancer 6 years after BAD diagnosis/matching was 1.6% in the BAD group and 1.1% in controls (P = 0.01). The ORs of total GI cancer 8 and 15 years before BAD diagnosis were 6.16 (5.08–7.48) and 5.19 (4.28–6.29), respectively. Furthermore, 47 individuals with BAD (0.9%) and 250 (0.5%) controls died of GI cancer. DISCUSSION: This nationwide cohort study indicates an association between BAD and GI cancers. We found both a higher incidence of GI cancer after BAD diagnosis compared with controls and increased OR of GI cancer before BAD diagnosis. Bearing in mind the underdiagnosis of BAD, the delay of BAD diagnosis, and the carcinogenic effect of bile acids, these findings warrant further investigations of the risk of GI cancer in individuals with BAD.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 5-6
Author Response to Letter to the Editor regarding “the Epidemiology of Bile Acid Diarrhea in Denmark” [Response to Letter]
Response to Letter in regards to The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]
- 1 January 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 5-6
Open AccessAuthor Response to Letter to the Editor regarding “the Epidemiology of Bile Acid Diarrhea in Denmark” [Response to Letter]
Response to Letter in regards to The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 7-8
The Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter]
Response to Letter in regards to The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]
- 1 January 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 7-8
Open AccessThe Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter]
Response to Letter in regards to The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]
- Open Access
- 1 December 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1173-1181
The Epidemiology of Bile Acid Diarrhea in Denmark
Objective: Bile acid diarrhea (BAD) is a socially debilitating disease with frequent bowel movements, urgency, and fecal incontinence as the main symptoms. It is caused by excessive bile acid levels in the colon and is most commonly treated with bile acid sequestrants. It is estimated that 1– 2% of the population suffers from the disease, but only a fraction of these are properly diagnosed with the gold standard ⁷⁵selenium-homotaurocholic acid (SeHCAT) test. Here, we use nationwide registries to describe the demographic characteristics of individuals suffering from BAD in Denmark. Methods: Since the International Classification of Diseases diagnosis code for BAD was not used until 2021, we identified the BAD population by referral to SeHCAT testing followed by a prescription of a bile acid sequestrant (colestyramine, colestipol or colesevelam) within 365 days. The study period was from 2003 to 2021. Results: During the study period, a total of 5264 individuals with BAD were identified with large differences between the five regions in Denmark. The number of prescriptions of colestyramine and colesevelam, the number of SeHCAT tests, and the number of individuals diagnosed with BAD increased during the study period. The BAD population had more co-morbidities and more health care contacts as well as lower levels of education and income compared with age- and sex-matched controls from the general population. Conclusion: Using the Danish registries, we identified a BAD population, which seems to be inferior in health care and socio-economic parameters compared with the Danish general population.
- 1 December 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1173-1181
Open AccessThe Epidemiology of Bile Acid Diarrhea in Denmark
Objective: Bile acid diarrhea (BAD) is a socially debilitating disease with frequent bowel movements, urgency, and fecal incontinence as the main symptoms. It is caused by excessive bile acid levels in the colon and is most commonly treated with bile acid sequestrants. It is estimated that 1– 2% of the population suffers from the disease, but only a fraction of these are properly diagnosed with the gold standard ⁷⁵selenium-homotaurocholic acid (SeHCAT) test. Here, we use nationwide registries to describe the demographic characteristics of individuals suffering from BAD in Denmark. Methods: Since the International Classification of Diseases diagnosis code for BAD was not used until 2021, we identified the BAD population by referral to SeHCAT testing followed by a prescription of a bile acid sequestrant (colestyramine, colestipol or colesevelam) within 365 days. The study period was from 2003 to 2021. Results: During the study period, a total of 5264 individuals with BAD were identified with large differences between the five regions in Denmark. The number of prescriptions of colestyramine and colesevelam, the number of SeHCAT tests, and the number of individuals diagnosed with BAD increased during the study period. The BAD population had more co-morbidities and more health care contacts as well as lower levels of education and income compared with age- and sex-matched controls from the general population. Conclusion: Using the Danish registries, we identified a BAD population, which seems to be inferior in health care and socio-economic parameters compared with the Danish general population.